Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02279823
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : March 13, 2017
Sponsor:
Information provided by (Responsible Party):
Intrepid Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE October 7, 2014
First Posted Date  ICMJE October 31, 2014
Last Update Posted Date March 13, 2017
Study Start Date  ICMJE October 2014
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 30, 2014)
  • Change in Target Area Hair Count (TAHC) [ Time Frame: Baseline and Month 6 ]
    Changes from Baseline in TAHC [in number of non-vellus hairs] using digital image analysis at Month 6.
  • Subject Self Assessment (Hair Growth Assessment [HGA]) [ Time Frame: Month 6 ]
    The subject's evaluation of treatment benefit via the HGA questionnaires at Month 6. Scalp hair growth is compared from baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 30, 2014)
  • Change in Target Area Hair Width (TAHW) [ Time Frame: Baseline and Month 6 ]
    Changes from Baseline in TAHW [in μm/cm2] using digital image analysis at Month 6.
  • Change in Target Area Hair Density (TAHD) [ Time Frame: Baseline and Month 6 ]
    Changes from Baseline in TAHD [in intensity units] using digital image analysis at Month 6.
  • Subject evaluation of treatment benefit via the Hair Growth Index (HGI) and Hair Growth Satisfaction Scale (HGSS) questionnaires [ Time Frame: Month 6 ]
    The subject's evaluation of treatment benefit via the HGI and HGSS questionnaires at Month 6. HGI: Hair growth is compared from baseline by three questions on a health outcome questionnaire, which are scored using the following 7-point scale: much less (-3), moderately less (-2), slightly less (-1), the same amount (0), slightly more (1), moderately more (2), much more (3). HGSS: Hair appearance/growth is compared from baseline by five questions, which are scored using the following 7-point scale: very dissatisfied (-3), dissatisfied (-2), somewhat dissatisfied (-1), neutral/neither satisfied nor dissatisfied (0), somewhat satisfied (1), satisfied (2), very satisfied (3).
  • Investigator's Global Assessment (IGA) [ Time Frame: Baseline, Month 2, 4 and 6 ]
    Compared to Baseline, the investigator will assess the subject's scalp hair growth using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
Official Title  ICMJE A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)
Brief Summary In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Androgenetic Alopecia
Intervention  ICMJE
  • Drug: CB-03-01 solution
    Investigational drug solution
    Other Name: cortexolone 17α-propionate
  • Drug: Minoxidil Solution 5%
    FDA approved marketed product
  • Drug: Placebo solution
    Vehicle solution
Study Arms  ICMJE
  • Experimental: CB-03-01 solution
    Topical solution applied twice daily for 26 weeks
    Intervention: Drug: CB-03-01 solution
  • Active Comparator: Minoxidil Solution 5%
    Topical solution applied twice daily for 26 weeks
    Intervention: Drug: Minoxidil Solution 5%
  • Placebo Comparator: Placebo solution
    Topical solution applied twice daily for 26 weeks
    Intervention: Drug: Placebo solution
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 15, 2016)
95
Original Estimated Enrollment  ICMJE
 (submitted: October 30, 2014)
90
Actual Study Completion Date  ICMJE May 2016
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject has mild to moderate androgenetic alopecia (AGA) in temple and vertex region
  • Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study
  • Subject agrees to continue his other general hair care products and regimen for the entire study
  • Subjects who are sexually active with a female partner must be surgically sterile or agree to use an effective method of birth control from the first administration of the test article until 30 days after the last administration

Exclusion Criteria:

  • Subject has any dermatological disorders of the scalp in the target region with the possibility of interfering with the application of the test article or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy
  • Subject has any condition in the opinion of the investigator that could interfere with the evaluation of the test articles or requires the use of interfering topical or systemic therapy (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns)
  • Subject has a current or recent history (within 3 months) of hair transplants, hair weaves or non-breathable wigs and hair bonding
  • Subject has a current or recent history (within 3 months) of active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania or conditions/diseases other than AGA
  • Subject has a current or recent history (within 3 months) of severe dietary changes or presenting a history of eating disorder(s)
  • Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study
  • Subject is currently enrolled in an investigational drug or device study
  • Subject has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment
  • Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
  • Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
  • The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles or tattoo ink
  • Subject has used any of the following topical preparations or procedures on the scalp:

    • Topical treatments including corticosteroids, pimecrolimus, tacrolimus, minoxidil, hormone therapy, anti-androgens or other agents that are known to affect hair growth in the opinion of the investigator within 12 weeks of the initiation of treatment
    • Topical over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Aminexil, Maxilene, Nioxin, Foltene, etc. or hair health or hair growth products with saw palmetto, copper, etc.) in the opinion of the investigator within 4 weeks of the initiation of treatment.
    • Scalp procedures (surgical, laser, light or energy treatments, etc.) within 6 months of the initiation of treatment
  • Subject has used the following systemic medications or procedures:

    • Beta blockers, cimetidine, diazoxide, isotretinoin, vitamin A intake above 10000 IU per day or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least 4 weeks prior to the initiation of treatment)
    • Retinoid, cyclosporine therapy within 6 months of the initiation of treatment
    • Finasteride (Propecia®, etc.), dutasteride or a similar product(s) within 12 months of the initiation of treatment
    • Chemotherapy, cytotoxic agents or radiation (of the scalp) within 12 months of the initiation of treatment
    • Other systemic therapy which may materially affect the subject's hair or hair growth in the opinion of the investigator
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02279823
Other Study ID Numbers  ICMJE 171-7152-201
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Intrepid Therapeutics, Inc.
Study Sponsor  ICMJE Intrepid Therapeutics, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Anthony Andrasfay Therapeutics, Inc.
PRS Account Intrepid Therapeutics, Inc.
Verification Date March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP